Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Selective inhibitor of aromatase (estrogen-synthetase), similar to anastrozole, which inhibits the secretion of estrogens.
It is used during the preoperative phase in positive hormone-receptor breast cancer in order to try breast-conserving surgery.
It is used in infertility treatments due to ovulation problems, luteal phase defects including polycystic ovarian syndrome.
Oral administration once a day for prolonged periods.
Since the last update date we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (low molecular weight, low protein binding and prolonged half-life) make transfer to milk likely in quantities that could be significant.
From pharmacokinetics it is known that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½, 94%, after 5 T½ 96.9%, after 6 T½ 98.4% and after 7 T½ 99%. From 7 T½ plasma drug concentrations in the body are negligible. In general, a period of five half-lives can be considered a safe waiting period before returning to breastfeeding (Anderson 2016).
Expert authors recommend waiting 10 days (5 T½) after the last dose to restart breastfeeding (Hale 2017 pp. 548), fewer than the manufacturer, which advises 21 days (Novartis 2017). In the meantime, express and discard breast milk regularly.
Its long elimination half-life and its administration every 24 hours over many months make it impossible to continue breastfeeding.